RT Journal Article
SR Electronic
T1 Correction to “Rimonabant, a Cannabinoid Receptor Type 1 Inverse Agonist, Inhibits Hepatocyte Lipogenesis by Activating Liver Kinase B1 and AMP-Activated Protein Kinase Axis Downstream of Gα<sub>i/o</sub> Inhibition”
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 561
OP 562
DO 10.1124/mol.82.3.561
VO 82
IS 3
YR 2012
UL http://molpharm.aspetjournals.org/content/82/3/561.abstract
AB